<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533453</url>
  </required_header>
  <id_info>
    <org_study_id>D5551L00018</org_study_id>
    <nct_id>NCT02533453</nct_id>
  </id_info>
  <brief_title>A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.</brief_title>
  <acronym>Bydureon</acronym>
  <official_title>A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As current study is conducted to provide additional information regarding safety and efficacy
      Bydureon, exenatide once weekly for injectable suspension, in the Korean population open
      label, non-comparative, multi-centre design is used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>•Percentage of patients with treatment-emergent adverse events (AEs) and serious adverse events (SAEs) in patients who are treated with 2 mg exenatide once weekly</measure>
    <time_frame>Assessed up to 12/24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Nature, incidence and severity of Adverse Events (AE) in patients who are treated with 2 mg exenatide once weekly.</measure>
    <time_frame>Assessed up to 12/24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Change in HbA1c at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)</measure>
    <time_frame>Assessed up to 12/24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in fasting plasma glucose at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)</measure>
    <time_frame>Assessed up to 12/24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in blood pressure at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)</measure>
    <time_frame>Assessed up to 12/24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in body weight at 4, 12 and 24 weeks from start of the treatment(24 weeks just for patients allocated in long-term treatment)</measure>
    <time_frame>Assessed up to 12/24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• &quot;Subjective improvement of main indication&quot; will be assessed as either &quot;improved,&quot; &quot;slightly improved,&quot; &quot;unchanged,&quot; &quot;aggravated,&quot; or &quot;unable to evaluate.&quot;</measure>
    <time_frame>Assessed up to 12/24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bydureon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bydureon</intervention_name>
    <description>exenatide once weekly</description>
    <arm_group_label>Bydureon</arm_group_label>
    <other_name>exenatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 19-75 years of age

          -  diagnosed with type 2 diabetes mellitus

          -  Patients who have not achieved adequate glycaemic control on maximally tolerated doses
             of these oral therapies;

               -  Metformin

               -  Sulphonylurea

               -  Thiazolidinedione

               -  Metformin and sulphonylurea

               -  Metformin and thiazolidinedione

        Exclusion Criteria:

          -  Has been treated, is currently being treated, or is expected to require or undergo
             treatment with any of the following medications:

               1. Alpha glucosidase inhibitor or meglitinide within 30 days of screening;

               2. Insulin within 2 weeks prior to screening or insulin for longer than 1 week
                  within 3 months of screening;

               3. DPP-4 inhibitors within 30 days of screening;

               4. Regular use (&gt; 14 days) of drugs that directly affect gastrointestinal motility
                  within 3 months of screening;

               5. Regular use (&gt; 14 days) of systemic corticosteroids by oral, intravenous, or
                  intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have
                  a high rate of systemic absorption within 3 months of screening;

               6. GLP-1 receptor agonist except exenatide within 3 months of screening;

          -  diagnosed with type 1 diabetes mellitus or diabetic ketoacidosis;

          -  type 2 diabetes by beta-cell dysfunction requiring insulin treatment

          -  Has ever used exenatide

          -  Pregnant or breast feeding patients

          -  Hepatic disease (defined by aspartate or alanine transaminase &gt;3.0 times the upper
             limit of normal

          -  End-stage renal disease or severe renal impairment (creatinine clearance &lt; 30 ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus, T2DM, GLP-1, GLP-1 Once weekly, Exenatide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 10, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

